Cancer

In April, the FDA warned of risk of secondary cancers in people receiving CAR-T cell therapy. A large Stanford Medicine study finds the risk is low and not related to the CAR-T cells.

The professor of dermatology and genetics was honored with the 2024 Lurie Prize for his studies into the role of long noncoding RNA in health and disease.

In a finding that vastly expands the understanding of tumor evolution, researchers discover genetic biomarkers that can predict the breast cancer subtype a patient is likely to develop.

A personal tragedy spurred Hahn, who had escaped Nazi Europe as a child, to pursue a career seeking new therapies for cancer.

The FDA recently approved the first cell-based therapy — widely used in treating blood cancers — for solid tumors. Stanford Medicine treated the first patient with advanced melanoma.

Artificial intelligence algorithms powered by deep learning improve skin cancer diagnostic accuracy for doctors, nurse practitioners and medical students in a study led by the Stanford Center for Digital Health.

Stanford Medicine researchers develop a new imaging method to create a cell-by-cell reconstruction of skin or other tissue without taking a biopsy.

Soft tissue sarcomas are rare and difficult to treat. Machine-learning tools designed at Stanford Medicine uncover distinct cellular communities that correlate with prognosis, immunotherapy success.

A Stanford Medicine study identifies an easily measured biophysical property that can identify Type 2 diabetics at increased risk for liver cancer who don’t meet current screening guidelines.

Treatment of metastatic disease is responsible for nearly one-third of the decrease in annual deaths from breast cancer from 1975 to 2019, according to a Stanford Medicine-led study.

Circulating tumor DNA predicts recurrence and splits disease into two subgroups in Stanford Medicine-led study of Hodgkin lymphoma. New drug targets or changes in treatments may reduce toxicity.